{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T01:27:10Z","timestamp":1697678830183},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T00:00:00Z","timestamp":1207785600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s12072-008-9066-1","type":"journal-article","created":{"date-parts":[[2008,4,9]],"date-time":"2008-04-09T15:12:44Z","timestamp":1207753964000},"page":"296-303","source":"Crossref","is-referenced-by-count":10,"title":["Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B"],"prefix":"10.1007","volume":"2","author":[{"given":"Rong-Nan","family":"Chien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,10]]},"reference":[{"key":"9066_CR1","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J","volume":"61","author":"RP Beasley","year":"1988","unstructured":"Beasley RP. Hepatitis B virus. The etiology of hepatocellular carcinoma. Cancer 1988;61:1942\u201356.","journal-title":"Cancer"},{"key":"9066_CR2","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1001\/jama.1991.03460150078027","volume":"265","author":"E Kaklamani","year":"1991","unstructured":"Kaklamani E, Trichopoulos D, Tzonou A, et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA 1991;265:1974\u20136.","journal-title":"JAMA"},{"key":"9066_CR3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.7326\/0003-4819-116-2-97","volume":"116","author":"RG Simonetti","year":"1992","unstructured":"Simonetti RG, Camma C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. Ann Intern Med 1992;116:97\u2013102.","journal-title":"Ann Intern Med"},{"key":"9066_CR4","first-page":"1101","volume":"22","author":"YF Liaw","year":"1995","unstructured":"Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995;22:1101\u20138.","journal-title":"Hepatology"},{"key":"9066_CR5","doi-asserted-by":"crossref","unstructured":"Consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615\u201324.","DOI":"10.1016\/j.jhep.2005.03.003"},{"key":"9066_CR6","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521\u201331.","journal-title":"N Engl J Med"},{"key":"9066_CR7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1046\/j.1440-1746.2001.02523.x","volume":"16","author":"YF Liaw","year":"2001","unstructured":"Liaw YF. Concurrent hepatitis B and C virus infection: is hepatitis C virus stronger? J Gastroenterol Hepatol 2001;16:597\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"9066_CR8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0016-5085(94)90076-0","volume":"107","author":"CM Chu","year":"1994","unstructured":"Chu CM, Sheen IS, Liaw YF. The role of hepatitis C virus in fulminant viral hepatitis in an endemic area of hepatitis A and B. Gastroenterology 1994;107:189\u201395.","journal-title":"Gastroenterology"},{"key":"9066_CR9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hep.1840140111","volume":"14","author":"TL Fong","year":"1991","unstructured":"Fong TL, Di Bisceglie AM, Waggoner JG, et al. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991;14:64\u20137.","journal-title":"Hepatology"},{"key":"9066_CR10","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1053\/jhep.2000.19288","volume":"32","author":"E Sagnelli","year":"2000","unstructured":"Sagnelli E, Coppola N, Scolastico C, et al. Virological and clinical aspects of reciprocal inhibitory effect of hepatitis B, C, and Delta viruses in patients with chronic hepatitis. Hepatology 2000;32:1106\u201310.","journal-title":"Hepatology"},{"key":"9066_CR11","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/1097-0142(19941101)74:9<2442::AID-CNCR2820740909>3.0.CO;2-#","volume":"74","author":"L Benvegnu","year":"1994","unstructured":"Benvegnu L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994;74:2442\u20138.","journal-title":"Cancer"},{"key":"9066_CR12","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.gastro.2004.01.011","volume":"126","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Chen YC, Sheen IS, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004;126:1024\u20139.","journal-title":"Gastroenterology"},{"key":"9066_CR13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/infdis\/170.2.358","volume":"170","author":"IS Sheen","year":"1994","unstructured":"Sheen IS, Liaw YF, Lin DY, Chu CM. Role of hepatitis C and delta viruses in the termination of chronic HBsAg carrier state: a multivariate analysis in a longitudinal follow-up study. J Infect Dis 1994;170:358\u201361.","journal-title":"J Infect Dis"},{"key":"9066_CR14","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1053\/jhep.2002.36509","volume":"36","author":"E Sagnelli","year":"2002","unstructured":"Sagnelli E, Coppola N, Messina V, et al. HBV superinfection in hepatitis C virus chronic carrier, viral interaction and clinical course. Hepatology 2002;36:1285\u201391.","journal-title":"Hepatology"},{"key":"9066_CR15","first-page":"169","volume-title":"Viral hepatitis","author":"JL Gerin","year":"2002","unstructured":"Gerin JL, Casey JL, Purcell RH. Hepatitis delta virus. In: Hollinger FB, Purcell RH, Gerin JL, editors. Viral hepatitis. Philadelphia: Lippincott Williams and Wilkins; 2002. p. 169\u201382."},{"key":"9066_CR16","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1016\/S0168-8278(03)00331-3","volume":"39","author":"P Farci","year":"2003","unstructured":"Farci P. Delta hepatitis: an update. J Hepatol 2003;39:S212\u20139.","journal-title":"J Hepatol"},{"key":"9066_CR17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7326\/0003-4819-98-4-437","volume":"98","author":"M Rizzetto","year":"1983","unstructured":"Rizzetto M, Verme G, Recchia S, et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983;98:437\u201341.","journal-title":"Ann Intern Med"},{"key":"9066_CR18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0168-8278(87)80032-6","volume":"5","author":"G Saracco","year":"1987","unstructured":"Saracco G, Rosina F, Brunetto MR, et al. Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol 1987;5:274\u201381.","journal-title":"J Hepatol"},{"key":"9066_CR19","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.21627","volume":"45","author":"JH Hoofnagle","year":"2007","unstructured":"Hoofnagle JH, Doo E, Liang J, et al. Management of hepatitis B: summary of a clinic research workshop. Hepatology 2007;45:1056\u201375.","journal-title":"Hepatology"},{"key":"9066_CR20","first-page":"27","volume":"4","author":"M Puoti","year":"2002","unstructured":"Puoti M, Airoldi M, Bruno R, et al. Hepatitis B virus co-infected subjects. AIDS Rev 2002;4:27\u201335.","journal-title":"AIDS Rev"},{"key":"9066_CR21","doi-asserted-by":"crossref","unstructured":"Brook MG, Gilson R, Wilkins E, on behalf of the British HIV Association. BHIVA guidelines: coinfection with HIV, chronic hepatitis B. HIV Med 2003;4:42\u201351.","DOI":"10.1046\/j.1468-1293.4.s1.1.x"},{"key":"9066_CR22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1086\/377135","volume":"188","author":"S Kellerman","year":"2003","unstructured":"Kellerman S, Hanson D, McNaghten A, Fleming P. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected subjects. J Infect Dis 2003;188:571\u20137.","journal-title":"J Infect Dis"},{"key":"9066_CR23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D Lavanchy","year":"2004","unstructured":"Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment. J Viral Hepat 2004;11:97\u2013107.","journal-title":"J Viral Hepat"},{"key":"9066_CR24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-2003-37586","volume":"23","author":"B Rehermann","year":"2003","unstructured":"Rehermann B. Immune responses in hepatitis B virus infection. Semin Liver Dis 2003;23:21\u201337.","journal-title":"Semin Liver Dis"},{"key":"9066_CR25","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/gast.2002.37061","volume":"123","author":"V Di Martino","year":"2002","unstructured":"Di Martino V, Thevenot T, Colin J. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002;123:1812\u201322.","journal-title":"Gastroenterology"},{"key":"9066_CR26","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1097\/00002030-200410210-00008","volume":"18","author":"M Bonacini","year":"2004","unstructured":"Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection, viral hepatitis B or C: a cohort study. AIDS 2004;18:2039\u201346.","journal-title":"AIDS"},{"key":"9066_CR27","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jhep.2005.11.015","volume":"44","author":"M Puoti","year":"2006","unstructured":"Puoti M, Torti C, Bruno R, et al. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006;44:S65\u201370.","journal-title":"J Hepatol"},{"key":"9066_CR28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2893.1995.tb00070.x","volume":"2","author":"MD Weltman","year":"1995","unstructured":"Weltman MD, Brotodihardjo A, Crewe EB, et al. Coinfection with hepatitis B and C or B, C and \u03b4 viruses results in severe chronic liver disease and responds poorly to interferon-\u03b1 treatment. J Viral Hepat 1995;2:39\u201345.","journal-title":"J Viral Hepat"},{"key":"9066_CR29","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/jir.1997.17.449","volume":"17","author":"YF Liaw","year":"1997","unstructured":"Liaw YF, Chien RN, Lin SM, et al. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res 1997;17:449\u201352.","journal-title":"J Interferon Cytokine Res"},{"key":"9066_CR30","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1111\/j.1572-0241.1999.01300.x","volume":"94","author":"G Mazzella","year":"1999","unstructured":"Mazzella G, Saracco G, Festi D, et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 1999;94:2246\u201350.","journal-title":"Am J Gastroenterol"},{"key":"9066_CR31","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1046\/j.1440-1746.1999.01952.x","volume":"14","author":"RC Guptan","year":"1999","unstructured":"Guptan RC, Thakur V, Raina V, Sarin SK. Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. J Gastroenterol Hepatol 1999;14:893\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"9066_CR32","first-page":"2973","volume":"96","author":"E Villa","year":"2001","unstructured":"Villa E, Grottola A, Buttafoco P, et al. High dose of \u03b1-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 2001;96:2973\u20137.","journal-title":"Am J Gastroenterol"},{"key":"9066_CR33","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jhep.2004.07.009","volume":"41","author":"A Marrone","year":"2004","unstructured":"Marrone A, Zampino R, D\u2019Onofrio M, et al. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J Hepatol 2004;41:1064\u20135.","journal-title":"J Hepatol"},{"key":"9066_CR34","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1053\/jhep.2003.50096","volume":"37","author":"CJ Liu","year":"2003","unstructured":"Liu CJ, Chen PJ, Lai MY, et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003;37:568\u201376.","journal-title":"Hepatology"},{"key":"9066_CR35","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1440-1746.2005.03791.x","volume":"20","author":"CH Hung","year":"2005","unstructured":"Hung CH, Lee CM, Lu SN, et al. Combination therapy with interferon-\u03b1 and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol 2005;20:727\u201332.","journal-title":"J Gastroenterol Hepatol"},{"key":"9066_CR36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/135965350501000111","volume":"10","author":"WL Chuang","year":"2005","unstructured":"Chuang WL, Dai CY, Chang WY, et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther 2005;10:125\u201333.","journal-title":"Antivir Ther"},{"key":"9066_CR37","doi-asserted-by":"crossref","first-page":"341A","DOI":"10.1002\/hep.21252","volume":"44","author":"RN Chien","year":"2006","unstructured":"Chien RN, Hu CC, Sheen IS, et al. The therapeutic effect of ribavirin plus pegylated interferon in chronic hepatitis B and C. Hepatology 2006;44:341A.","journal-title":"Hepatology"},{"key":"9066_CR38","doi-asserted-by":"crossref","first-page":"616A","DOI":"10.1016\/j.jhep.2005.11.041","volume":"44","author":"CJ Liu","year":"2006","unstructured":"Liu CJ, Chen PJ, Kao JH, et al. An open label comparative multicenter study of peginterferon alfa-2a plus ribavirin in the treatment of patients with chronic hepatitis C\/hepatitis B co-infection versus those with monoinfected chronic hepatitis C: an interim report. Hepatology 2006;44:616A.","journal-title":"Hepatology"},{"key":"9066_CR39","first-page":"291","volume-title":"The hepatitis delta virus and its infection: progress in clinical and biological research","author":"F Rosina","year":"1987","unstructured":"Rosina F, Saracco G, Lattore V, et al. Treatment of chronic delta hepatitis with recombinant human alpha interferon. In: Rizzetto M, Gerin JL, Purcell RH, editors. The hepatitis delta virus and its infection: progress in clinical and biological research. New York: Alan R. Liss; 1987. p. 291\u20138."},{"key":"9066_CR40","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/0168-8278(89)90143-8","volume":"9","author":"JC Porres","year":"1989","unstructured":"Porres JC, Carreno V, Bartolome J, et al. Treatment of chronic delta infection with recombinant human interferon alpha 2c at high doses. J Hepatol 1989;9:338\u201344.","journal-title":"J Hepatol"},{"key":"9066_CR41","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/hep.1840130608","volume":"13","author":"F Rosina","year":"1991","unstructured":"Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-\u03b1 in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991;13:1052\u20136.","journal-title":"Hepatology"},{"key":"9066_CR42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1056\/NEJM199401133300202","volume":"330","author":"P Farci","year":"1994","unstructured":"Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994;330:88\u201394.","journal-title":"N Engl J Med"},{"key":"9066_CR43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2893.1996.tb00002.x","volume":"3","author":"V Di Marco","year":"1996","unstructured":"Di Marco V, Giacchino R, Timitilli A, et al. Long-term interferon-\u03b1 treatment of children with chronic hepatitis delta: a multicentre study. J Viral Hepat 1996;3:123\u20138.","journal-title":"J Viral Hepat"},{"key":"9066_CR44","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","volume":"126","author":"P Farci","year":"2004","unstructured":"Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon \u03b1 therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004;126:1740\u20139.","journal-title":"Gastroenterology"},{"key":"9066_CR45","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep.21325","volume":"44","author":"C Castelnau","year":"2006","unstructured":"Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006;44:728\u201335.","journal-title":"Hepatology"},{"key":"9066_CR46","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","volume":"44","author":"GA Niro","year":"2006","unstructured":"Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006;44:713\u201320.","journal-title":"Hepatology"},{"key":"9066_CR47","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/135965350501000603","volume":"10","author":"F Gunsar","year":"2005","unstructured":"Gunsar F, Akarca US, Ersoz G, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 2005;10:721\u20136.","journal-title":"Antivir Ther"},{"key":"9066_CR48","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.49.3.1135-1138.2005","volume":"49","author":"S Kaymakoglu","year":"2005","unstructured":"Kaymakoglu S, Karaca C, Demir K, et al. Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother 2005;49:1135\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"9066_CR49","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.510300217","volume":"30","author":"DT Lau","year":"1999","unstructured":"Lau DT, Doo E, Park Y, et al. Lamivudine for chronic delta hepatitis. Hepatology 1999;30:546\u20139.","journal-title":"Hepatology"},{"key":"9066_CR50","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1046\/j.1365-2893.2000.00254.x","volume":"7","author":"LM Wolters","year":"2000","unstructured":"Wolters LM, van Nunch AB, Hookoop P, et al. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 2000;7:428\u201334.","journal-title":"J Viral Hepat"},{"key":"9066_CR51","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.jhep.2005.11.019","volume":"44","author":"Y Benhamou","year":"2006","unstructured":"Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol 2006;44:S90\u20134.","journal-title":"J Hepatol"},{"key":"9066_CR52","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0140-6736(01)05840-8","volume":"358","author":"Y Benhamou","year":"2001","unstructured":"Benhamou Y, Bochet M, Thibaut V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718\u201323.","journal-title":"Lancet"},{"key":"9066_CR53","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.aids.0000163948.62176.e7","volume":"19","author":"V Soriano","year":"2005","unstructured":"Soriano V, Puoti M, Bonacini M, et al. Care of patients with chornic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005;19:221\u201340.","journal-title":"AIDS"},{"key":"9066_CR54","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1055\/s-2005-915646","volume":"25","author":"NJ Shire","year":"2005","unstructured":"Shire NJ, Sherman KE. Management of HBV\/HIV coinfected patients. Semin Liver Dis 2005;25:S48\u201357.","journal-title":"Semin Liver Dis"},{"key":"9066_CR55","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1086\/380398","volume":"189","author":"GT Dore","year":"2004","unstructured":"Dore GT, Cooper D, Pozniak A, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004;189:1185\u201392.","journal-title":"J Infect Dis"},{"key":"9066_CR56","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1056\/NEJMoa067710","volume":"356","author":"MA McMahon","year":"2007","unstructured":"McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir\u2014effects on HIV-1 replication and resistance. N Engl J Med 2007;356:2614\u201321.","journal-title":"N Engl J Med"},{"key":"9066_CR57","first-page":"1030","volume":"31","author":"Y Benhamou","year":"2000","unstructured":"Benhamou Y, Bocher M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 2000;31:1030\u20131.","journal-title":"Hepatology"},{"key":"9066_CR58","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1097\/01.aids.0000247116.89455.5d","volume":"20","author":"G Schmutz","year":"2006","unstructured":"Schmutz G, Nelson M, Lutz T, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006;20:1951\u20134.","journal-title":"AIDS"},{"key":"9066_CR59","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","volume":"296","author":"SM Hammer","year":"2006","unstructured":"Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the international AIDS Society-USA Panels. JAMA 2006;296:827\u201343.","journal-title":"JAMA"},{"key":"9066_CR60","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/hep.21055","volume":"43","author":"Y Benhamou","year":"2006","unstructured":"Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV infected patients. Hepatology 2006;43:548\u201355.","journal-title":"Hepatology"},{"key":"9066_CR61","first-page":"1062","volume":"39","author":"F Bani-Sadr","year":"2004","unstructured":"Bani-Sadr F, Palmer P, Scieux C, Molina JM. Ninety-six week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild type hepatitis B virus. J Infect Dis 2004;39:1062\u20134.","journal-title":"J Infect Dis"},{"key":"9066_CR62","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/00002030-200301030-00002","volume":"17","author":"M Nelson","year":"2003","unstructured":"Nelson M, Portsmouth S, Stebbing J. An open-label study of tenofovir in HIV-1 and hepatitis B virus coinfected individuals. AIDS 2003;17:F7\u201310.","journal-title":"AIDS"},{"key":"9066_CR63","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1097\/00002030-200411190-00014","volume":"18","author":"O Schildgen","year":"2004","unstructured":"Schildgen O, Schewe C, Vogel M, et al. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS 2004;18:2325\u20137.","journal-title":"AIDS"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-008-9066-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-008-9066-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-008-9066-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T15:29:51Z","timestamp":1684337391000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-008-9066-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,10]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["9066"],"URL":"https:\/\/doi.org\/10.1007\/s12072-008-9066-1","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,10]]}}}